Oscient Will Pursue Factive Sinusitis Claim Despite FDA Refusal To File
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA accepted Oscient’s sNDA for gemifloxacin for the five-day treatment of mild to moderate community-acquired pneumonia.